Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acetaminophen Proposals Could Hit Firms Hard Via Sales And Costs

This article was originally published in The Tan Sheet

Executive Summary

Acetaminophen product manufacturers stand to incur huge costs and reduced revenue opportunities if FDA implements a working group's recommendations to reduce hepatotoxicity risk

You may also be interested in...



U.K. Tightens Restrictions On Nonprescription Pain Reliever Sales

The U.K. Medicines and Healthcare products Regulatory Agency recommends retailers restrict sales of nonprescription pain relievers to two packs per transaction to reduce the risk of overdose - a strategy an FDA working group rejected

U.K. Tightens Restrictions On Nonprescription Pain Reliever Sales

The U.K. Medicines and Healthcare products Regulatory Agency recommends retailers restrict sales of nonprescription pain relievers to two packs per transaction to reduce the risk of overdose - a strategy an FDA working group rejected

U.K. Tightens Restrictions On Nonprescription Pain Reliever Sales

The U.K. Medicines and Healthcare products Regulatory Agency recommends retailers restrict sales of nonprescription pain relievers to two packs per transaction to reduce the risk of overdose - a strategy an FDA working group rejected

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel